Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 202 Show results per page	View Search Criteria \| Help With Results

First Published: 11/14/2007


1.		Phase IV Study of Chemoresistance Markers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				CHUL-BIO-COLON RECF0356, INCA-RECF0356, NCT00559676

Last Modified: 6/15/2007 First Published: 5/23/2005


2.		Phase II/III Randomized Study of Oxaliplatin, Irinotecan, Leucovorin Calcium, and Fluorouracil Versus Gemcitabine as First-Line Chemotherapy in Patients With Metastatic Adenocarcinoma of the Pancreas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 75				Other				FRE-FNCLCC-ACCORD-11/0402 EU-20512, NCT00112658


3.		First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				D8480C00013 Eudract Number 2005-003440-66, NCT00384176


4.		FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				STX0206 NCT00724503


5.		FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				STX0207 NCT00735241


6.		Chemotherapy With or Without Enoxaparin in Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				CONKO 004 CCT-NAPN-16752, NCT00785421

Last Modified: 12/28/2008 First Published: 4/1/1999


7.		Phase III Randomized Study of Dexamethasone Versus Prednisolone During Induction Therapy and Prolonged Versus Conventional Duration Asparaginase During Consolidation and Late Intensification Therapy in Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 18				Other				EORTC-58951 NCT00003728

Last Modified: 2/12/2008 First Published: 11/1/2000


8.		Phase III Randomized Study of Induction and Maintenance Chemotherapy Regimens With Different Doses and Schedules of Methotrexate From the Berlin-Frankfurt-Munster-K2 Protocol With or Without Vinblastine in Children With Anaplastic Large Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 22				Other				FRE-IGR-ALCL99 EU-20031, NHL2000/06, NCT00006455

Last Modified: 6/14/2006 First Published: 10/1/2002


9.		Phase III Randomized Study of Adjuvant Chronomodulated Versus Standard Schedule Fluorouracil and Leucovorin Calcium With or Without Carboplatin in Patients With Completely Resected Stage IIB or III Colon Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				GRECCR-03 EU-20201, NCT00046995

Last Modified: 1/14/2009 First Published: 11/24/2002


10.		Phase III Randomized Study of Adjuvant Chemoradiation After Resection in Patients With Gastric or Gastroesophageal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-80101 NCCTG-CALGB-80101, ECOG-CALGB-80101, NCT00052910

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute